Disclosed are an anti human tumor necrosis factor α humanized antibody and a fragment antigen binding (Fab) thereof. The disclosure includes a composition for the antibody or the fragment antigen binding (Fab), and the use of the antibody or fragment antigen binding (Fab) in treating diseases related to tumor necrosis factor α.